BACKGROUND: To follow-up clinical and biochemical features in patients with Crohn's disease (CD) of the upper gastrointestinal (GI) tract and to evaluate the impact of different therapeutics on the outcome of these patients. METHODS: 32 CD patients with endoscopically and histologically proven CD of the upper GI tract were included into this retrospective study. Gastroduodenal and intestinal permeability tests, inflammatory parameters, Crohn's Disease Activity Index (CDAI), and upper gastrointestinal complaint profile were sequentially assessed. These parameters were assessed at the beginning and followed up during therapies with antisecretory drugs, mesalamine, prednisolone, and azathioprine. RESULTS: Symptoms responded to antisecretory drugs. Gastroduodenal permeability increased under mesalamine. Gastroduodenal and intestinal permeability as well as CDAI decreased under prednisolone. Under azathioprine, gastroduodenal and intestinal permeability, CDAI, and C-reactive protein decreased.
BACKGROUND: To follow-up clinical and biochemical features in patients with Crohn's disease (CD) of the upper gastrointestinal (GI) tract and to evaluate the impact of different therapeutics on the outcome of these patients. METHODS: 32 CD patients with endoscopically and histologically proven CD of the upper GI tract were included into this retrospective study. Gastroduodenal and intestinal permeability tests, inflammatory parameters, Crohn's Disease Activity Index (CDAI), and upper gastrointestinal complaint profile were sequentially assessed. These parameters were assessed at the beginning and followed up during therapies with antisecretory drugs, mesalamine, prednisolone, and azathioprine. RESULTS: Symptoms responded to antisecretory drugs. Gastroduodenal permeability increased under mesalamine. Gastroduodenal and intestinal permeability as well as CDAI decreased under prednisolone. Under azathioprine, gastroduodenal and intestinal permeability, CDAI, and C-reactive protein decreased.
Authors: Rana Al-Sadi; Shuhong Guo; Karol Dokladny; Matthew A Smith; Dongmei Ye; Archana Kaza; D Martin Watterson; Thomas Y Ma Journal: J Interferon Cytokine Res Date: 2012-07-20 Impact factor: 2.607
Authors: S Buhner; C Buning; J Genschel; K Kling; D Herrmann; A Dignass; I Kuechler; S Krueger; H H-J Schmidt; H Lochs Journal: Gut Date: 2005-07-06 Impact factor: 23.059
Authors: Michel A Boivin; Dongmei Ye; John C Kennedy; Rana Al-Sadi; Chris Shepela; Thomas Y Ma Journal: Am J Physiol Gastrointest Liver Physiol Date: 2006-10-26 Impact factor: 4.052
Authors: Sachin B Ingle; Baban D Adgaonkar; Nawab P Jamadar; Saleha Siddiqui; Chitra R Hinge Journal: World J Clin Cases Date: 2015-06-16 Impact factor: 1.337